EOFLOW v Insulet (CFI, 22 July 2025)
| Date | 22 July 2025 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Revocation Action |
| Registry reference | ACT_56003/2024 · ORD_69390/2024 |
| Parties | EOFLOW Co., Ltd. v. Insulet Corporation |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In a decision of 22 July 2025 (UPC_CFI_597/2024), given both on EOFLOW’s revocation action and on Insulet’s counterclaim for infringement, the Milan Central Division dismissed by default the revocation action against unitary patent EP 4 201 327, EOFLOW having refused to provide the EUR 500,000 security ordered, and then held that the EOPatch insulin pump (GlucoMen Day Pump) infringes claim 1. It granted an injunction backed by penalty payments, corrective measures, an information order and an interim award of EUR 230,000 in damages. It matters in practice for the consequence of failing to provide security and for the treatment of costs where the proprietor ran parallel proceedings against the manufacturer and the distributor.
Facts and procedure
On 3 July 2024 Insulet applied for provisional measures against EOFLOW before the Central Division and against its distributor Menarini before the Milan Local Division. EOFLOW brought its revocation action on 14 October 2024. The application for provisional measures, refused on 22 November 2024, was granted by the Court of Appeal on 30 April 2025. On 10 December 2024 Insulet filed its defence, applications to amend and its counterclaim. By order of 11 April 2025 EOFLOW was required to provide EUR 500,000 in security, the deadline later moved to 13 May 2025, at the interim conference that day EOFLOW stated that it would not pay, and Insulet requested a decision by default.
The applicable law
Rule 355 allows a decision by default where a party fails to comply with an order. Rule 355.2 requires that the facts put forward justify the remedy. Article 69(4) UPCA allows security for costs to be ordered. Corrective measures and the information order rest on Articles 64 and 67 UPCA, the interim award of damages on Rule 119, and the ceiling on recoverable costs on Rule 152.2.
Question
Does the revocation claimant’s refusal to provide the security ordered justify dismissing its action by default, and does the EOPatch pump fall within claim 1, in particular as regards the nut and the clutch of the drive mechanism?
Decision
The conditions for a decision by default were met: failure to comply with a validly issued order and a request by the other party. Dismissal served the purpose of Article 69(4), which protects a defendant against a claimant lacking the means to cover its costs, as the Court of Appeal noted on 20 June 2025 (UPC_CoA_393/2025). The sanction under Rule 355.2 is losing the case, not losing the patent. The applications to amend therefore did not need to be decided. On the counterclaim, a decision by default would have served no purpose, since the merits still had to be assessed, and the Court proceeded to a hearing. It construed the nut as a partially threaded tube nut, relying on dependent claim 2, and read “pass through” dynamically. The description and drawings act as the patent’s own lexicon without confining the claims to the preferred embodiment. All features of claim 1 were found. The Menarini settlement, filed late without leave, was disregarded. Exhaustion failed because consent was not tied to individual products. The infringement was held serious given its scale, justifying all corrective measures requested with no grace period. Penalty payments were set at EUR 30,000 per day for the injunction and EUR 15,000 for the other orders. The EUR 230,000 was fixed on an equitable basis, by reference to 69,723 units sold and a profit of at least EUR 3 per unit. The EUR 600,000 ceiling applies per instance whatever the number of parties or patents. The costs of two parallel legal teams were not recoverable and Menarini’s EUR 600,000 payment was credited, leaving EOFLOW liable for EUR 162,292 for the provisional measures proceedings, plus an interim EUR 200,000 towards the costs on the merits.
Key points for practice
- A revocation claimant that fails to provide the security ordered risks having its action dismissed by default, without any review of validity.
- A decision by default requires that the facts on file justify the remedy. It does not mechanically punish procedural conduct.
- A proprietor that runs parallel proceedings against manufacturer and distributor will not recover its costs twice, the ceiling applying per instance.
- Practical point: a settlement with a distributor must be filed in time, with the products it covers identified, if it is to support an exhaustion defence.
Provisions applied
- Agreement on a Unified Patent Court
- Arts 29, 63, 64, 67, 68, 69(4), 70 and 82(4)
- Rules of Procedure
- Rules 118, 119, 150, 151, 152, 157, 158, 171, 220, 221, 263, 350, 354, 355 and 356
- European Patent Convention
- Arts 54, 56, 69 and 138(1)
- Directive 2004/48/EC
- Art. 13
- Case law cited
- Court of Appeal, 20 June 2025, UPC_CoA_393/2025, Insulet v EOFlow, Court of Appeal, 30 April 2025, UPC_CoA_768/2024, Hanshow v VusionGroup, Court of Appeal, 29 July 2024, Meril v Edwards, Munich Local Division, 10 January 2025.
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Revocation action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- defendantInsulet Corporation26 decisions in the corpusFollow this party
- claimantEOFLOW Co., Ltd.22 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Revocation Action
- Outcome (Dhenne Avocats summary)
- L’action en nullité d’EOFLOW est rejetée par défaut faute de constitution de la garantie ordonnée. La pompe EOPatch contrefait la revendication 1 du brevet EP 4 201 327, avec interdiction sous astreinte, mesures correctives, information et provision de 230 000 euros.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 201 327mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- EOFLOW v Insulet (CFI, 11 April 2025) cited in this record
- Edwards Lifesciences v Meril (CFI, 10 January 2025) cited in this record
- Hanshow Technology v VusionGroup (CoA, 29 July 2024) cited in this record
- Insulet v EOFLOW (CFI, 22 July 2025) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 201 327Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith recorded proprietor: Insulet Corp | Patent at issue according to the summary or official headnote Also mentioned in 25 other decision(s): EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: summary of the decision, Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.